IHP THERAPEUTICS, INC.

Biotech · Private

IHP-100, a novel glycan-based biologic therapeutic that inhibits P-selectin and complement to prevent vaso-occlusive crisis in sickle cell disease

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $2.6M

Federal grants: $2.6M; 3 awards · 2023–2024; Rank in peer group#399 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 10 pending

Capital timeline

Latest events

Jun 2024Federal grantHealth and Human S · Phase II · Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease$1.2M
Aug 2023Federal grantHealth and Human S · Phase II · Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease$1.1M
Mar 2023Federal grantHealth and Human S · Phase II · Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease$301K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 10

Nov 27, 2025PendingChemically Modified HeparinUSPTOApplication 18872250
Nov 20, 2025PendingChemically Modified HeparinUSPTOApplication 18872252
Aug 3, 2023PendingPartially Desulfated Heparin For Treating Coronaviral InfectionsUSPTOApplication 18009654

Show all 10 patent records

Chemically Modified HeparinNov 27, 2025 · Application 18872250Pending
Chemically Modified HeparinNov 20, 2025 · Application 18872252Pending
Partially Desulfated Heparin For Treating Coronaviral InfectionsAug 3, 2023 · Application 18009654Pending
Chemically Modified HeparinApplication PCTUS2023024577Pending
Chemically Modified HeparinApplication 63349416Pending
Chemically Modified HeparinApplication 63349395Pending
Partially Desulfated Heparin For Treating Coronaviral InfectionsApplication PCTUS2021037265Pending
Partially Desulfated Heparin For Treating Coronaviral InfectionsApplication 63067702Pending
Partially Desulfated Heparin For Treating Coronaviral InfectionsApplication 63038472Pending
Chemically Modified HeparinApplication PCTUS2023024568Pending

NewcelX Ltd.Similar federal contract value in Biotech · null in contracts
HCW Biologics Inc.Similar federal contract value in Biotech · null in contracts
Onchilles Pharma, Inc.Similar federal contract value in Biotech · null in contracts
Cytoagents, Inc.Similar federal contract value in Biotech · null in contracts
Aromyx CorpSimilar federal contract value in Biotech · null in contracts
MODULO BIO, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.